Sign In
Buy NTRA
$318.35
-3.75 (-1.16%)
At Close: Aug 10, 2026
Natera, Inc. $NTRA Shares Sold by California Public Employees Retirement System
04:50am, Wednesday, 22'nd Jul 2026
California Public Employees Retirement System lessened its stake in shares of Natera, Inc. (NASDAQ: NTRA) by 23.4% in the undefined quarter, according to its most recent Form 13F filing with the Secur
Fifth Third Bancorp Acquires 10,929 Shares of Natera, Inc. $NTRA
04:05am, Wednesday, 22'nd Jul 2026
Fifth Third Bancorp boosted its holdings in shares of Natera, Inc. (NASDAQ: NTRA) by 3,373.1% during the first quarter, according to the company in its most recent filing with the Securities and Excha
Amova Asset Management Americas Inc. Has $84.69 Million Stake in Natera, Inc. $NTRA
03:14am, Tuesday, 21'st Jul 2026
Amova Asset Management Americas Inc. reduced its position in Natera, Inc. (NASDAQ: NTRA) by 10.1% in the undefined quarter, according to the company in its most recent disclosure with the Securities a
Billionaire Investor Stanley Druckenmiller's Top 5 Picks: Worth Buying Today?
11:36am, Monday, 20'th Jul 2026
Stanley Druckenmiller doesn't do consensus. The Duquesne Family Office's latest 13F reveals a top-five long book that skips the mega-cap tech herd almost entirely: a Mexican discount grocer, two biote
Allspring Global Investments Holdings LLC Acquires 8,979 Shares of Natera, Inc. $NTRA
03:08am, Saturday, 18'th Jul 2026
Allspring Global Investments Holdings LLC grew its holdings in Natera, Inc. (NASDAQ: NTRA) by 2.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Co
Finalized MolDx LCD Includes Expanded Coverage for Natera's Prospera™ Portfolio
06:35pm, Thursday, 16'th Jul 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted the impact of a final local coverage determination (LCD) for mol
Billionaire Stanley Druckenmiller's Top Holding Isn't Nvidia. Instead, It's This Under-the-Radar Stock That Wall Street Loves.
08:00am, Thursday, 16'th Jul 2026
It may not be a familiar name, but Natera has provided better returns than Nvidia over the past 12 months.
NTRA's Signatera Gains EU IVDR Certification for Multiple Cancers
11:01am, Friday, 10'th Jul 2026
Natera's Signatera became the first personalized MRD test for solid tumors to earn EU IVDR certification, supporting broader expansion across Europe.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:56am, Thursday, 09'th Jul 2026
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
06:00am, Thursday, 09'th Jul 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received certification as a Class C device unde
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
06:00am, Monday, 06'th Jul 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in JAMA Oncology, evaluating the utili
NTRA & Aveta Partner to Advance MRD-Guided Trial in Head & Neck Cancer
12:01pm, Wednesday, 01'st Jul 2026
Natera's Aveta partnership brings Signatera into a global Phase 3 head and neck cancer trial to assess MRD and treatment response.
Natera, Aveta partner on late-stage head and neck cancer trial
06:55am, Monday, 29'th Jun 2026
Genetic testing firm Natera and cancer drug developer Aveta Biomics said on Monday they have partnered on a late-stage study of an experimental therapy for head and neck cancer, in a bid to impr
AUSTIN, Texas & BEDFORD, Mass.--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Aveta Biomics, Inc., a clinical-stage immuno-oncology company
NTRA's Signatera Secures PMDA Approval for MRD Testing in CRC in Japan
10:55am, Thursday, 25'th Jun 2026
Natera's Signatera gains Japan PMDA approval for CRC, marking the country's first approved MRD test and advancing its global expansion.
